Compare SIGA & CMTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIGA | CMTG |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.8M | 339.3M |
| IPO Year | 2016 | 2016 |
| Metric | SIGA | CMTG |
|---|---|---|
| Price | $3.57 | $2.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 631.0K | ★ 828.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $187,828,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | $5.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.40 | $2.05 |
| 52 Week High | $9.62 | $3.99 |
| Indicator | SIGA | CMTG |
|---|---|---|
| Relative Strength Index (RSI) | 39.41 | 44.90 |
| Support Level | N/A | $2.11 |
| Resistance Level | $4.84 | $2.97 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 30.91 | 29.49 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Claros Mortgage Trust Inc is a real estate investment trust. The company is focused mainly on creating a diversified portfolio of income-producing loans collateralized by institutional-quality commercial real estate.